Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies (Nasdaq:ITCI) announced that CEO Sharon Mates, Ph.D., will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intra-Cellular Therapies (Nasdaq:ITCI) announced that CEO Sharon Mates, Ph.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 9:10 AM ET. The conference will be accessible via a live and archived webcast on the company's website, requiring registration 5-10 minutes prior to the event.
Intra-Cellular Therapies focuses on developing therapeutics for central nervous system disorders, leveraging Nobel prize-winning research to create innovative treatments for complex psychiatric and neurologic diseases.
Details
News Market Reaction – ITCI
The recorded move for ITCI in the trading session of this news was +0.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:10 am ET.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
CONTACT:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Lisa Burns
John Grimaldi
jgrimaldi@burnsmc.com
212-213-0006
Source: Intra-Cellular Therapies Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.